Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/10/16Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Proliferative Effects of its First-in-Class Selective RARα Agonist in Genomically Defined Subsets of Breast Cancer
– SY-1425 Inhibited Tumor Growth as a Single Agent in Preclinical Models of Drug-Resistant Breast Cancer with High RARA Gene Expression – – SY-1425 in Combination with Standard-of-Care Breast Cancer Therapies Shows Synergistic Effects in Multiple Preclinical Models – – Data Highlighted in Late-Breaking Presentation at San Antonio Breast Cancer Symposium – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 10, 2016-- Syros Pharmaceuticals ... 
Printer Friendly Version
12/05/16Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-in-Class Selective RARα Agonist for Genomically Defined Subsets of AML and MDS Patients
SY-1425 Induces Similar Biological Changes in Preclinical Models of a Novel AML Subset as It Does In APL, the Approved Indication in Japan, Supporting Syros’ Clinical Development Strategy Data Provide Support for Clinical Investigation of SY-1425 in Combination with Standard-of-Care AML and MDS Therapies Company Reveals Pharmacodynamic Markers to Measure Early Signs of Biological Activity in Ongoing Phase 2 Clinical Trial CAMBR... 
Printer Friendly Version
11/21/16Syros Pharmaceuticals Announces Late-Breaking Presentation on SY-1425 at San Antonio Breast Cancer Symposium
First-in-Class Potent and Selective RARα Agonist Represents New Potential Therapeutic Approach for Genomically Defined Subsets of Breast Cancer Patients CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 21, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) today announced that new data on its lead candidate, SY-1425, a selective retinoic acid receptor alpha (RARα) agonist, will be highlighted in a late-breaking presentation at the San Antonio Breast Cancer Sy... 
Printer Friendly Version
11/14/16Syros Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
Initiated Phase 2 Trial for SY-1425 in Genomically Defined Subsets of Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Highlighted Research on First Selective CDK12 and CDK13 Inhibitor as Novel Approach to Treat Range of Cancers Closed Initial Public Offering for $57.5 Million in Gross Proceeds CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 14, 2016-- Syros Pharmaceuticals (NASDAQ:SYRS) today reported finan... 
Printer Friendly Version
11/08/16Syros Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) announced today that members of its management team will present a corporate overview and participate in a panel discussion at upcoming investor conferences. Details are as follows: Stifel 2016 Healthcare Conference Date: Tuesday, November 15 Presentation Time: 1:30 p.m. ET Location: The Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY ... 
Printer Friendly Version
11/03/16Syros Pharmaceuticals to Present New Data on SY-1425, Its First-in-Class Potent and Selective RARα Agonist, at the ASH Annual Meeting
Data to Further Support the Potential of SY-1425 in AML by Showing Similar Biological Responses in Preclinical Models of AML and APL, the Approved Indication in Japan Presentation to Describe Pharmacodynamic Markers to Measure Early Signs of Biological Activity in Ongoing Phase 2 Clinical Trial CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 3, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) today announced that new data on its lead candidate, SY-... 
Printer Friendly Version
10/11/16Syros Announces Approval of Investigational Device Exemption (IDE) for Blood Test to Identify Cancer Patients with Proprietary Biomarkers
IDE Allows Syros to Expand Ongoing Phase 2 Clinical Trial of SY-1425 into Newly Diagnosed Acute Myeloid Leukemia and Low-Risk Myelodysplastic Syndrome Patients CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 11, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for a laboratory-based blood test to detect proprietary biomarkers discovered u... 
Printer Friendly Version
09/26/16Syros Announces Appointment of Gerald E. Quirk as Chief Legal Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 26, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) today announced the appointment of industry veteran Gerald E. Quirk as the Company’s first Chief Legal Officer. In this newly created role, Mr. Quirk will hold broad management responsibility for all legal aspects of the business, including corporate and securities law, intellectual property matters, business development transactions and compliance. “Sy... 
Printer Friendly Version
09/22/16Syros Announces First Patient Enrolled in Phase 2 Clinical Trial of SY-1425 in Genomically Defined Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 22, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) announced today that the first patient has been dosed in the Phase 2 clinical trial of its lead drug candidate, SY-1425, a first-in-class selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) identified using a novel biomarke... 
Printer Friendly Version
09/07/16Syros Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 7, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) announced today that its management team will participate in the upcoming Morgan Stanley Global Healthcare Conference. Details are as follows: Morgan Stanley Global Healthcare Conference Date: Wednesday, September 14 Location: Grand Hyatt New York, 109 East 42nd Street, New York, NY About Syros Pharmaceuticals Syros Pharmaceuticals is p... 
Printer Friendly Version
08/29/16Syros’ Scientific Founders Publish on First Selective CDK12 and CDK13 Inhibitor as Promising Approach for Treatment of Cancer
Novel Small Molecule Approach to Targeting Transcriptional Kinases Validates CDK12 and CDK13 Biology in Cancer Syros Holds Exclusive Rights to Research, Develop and Commercialize This and Related Selective Small Molecule Inhibitors Research Findings Published in Nature Chemical Biology CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 29, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) announced today that research from its scientific founde... 
Printer Friendly Version
08/26/16Syros Pharmaceuticals to Present at BioCentury NewsMakers Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 26, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) announced today that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference. Details are as follows: BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference Date: Friday, September 9 Time: 2-2:25 p.m. Location: Millennium Broadway Hot... 
Printer Friendly Version
08/15/16Syros Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
Successfully Completed Initial Public Offering Raising $57.5 Million in Gross Proceeds Phase 2 Trial of SY-1425 Opened for Enrollment for Genomically Defined Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 15, 2016-- Syros Pharmaceuticals (NASDAQ:SYRS) today reported financial results for the second quarter ended June 30, 2016, and provided an update on recent ... 
Printer Friendly Version
08/03/16Syros Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 3, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) announced today that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at the Wedbush PacGrow Healthcare Conference. Details are as follows: Wedbush PacGrow Healthcare Conference Date: Tuesday, August 16 Time: 10:55 a.m. Location: Le Parker Meridien Hotel, 119 West 56th Street, New York, NY A live webca... 
Printer Friendly Version
07/06/16Syros Pharmaceuticals Announces Closing of Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 6, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) today announced the closing of its initial public offering of 4,600,000 shares of common stock at an offering price of $12.50 per share, including 600,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Syros. The gross proceeds from the initial public... 
Printer Friendly Version
06/29/16Syros Pharmaceuticals Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 29, 2016-- Syros Pharmaceuticals today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $12.50 per share, before underwriting discounts and commissions. In addition, Syros has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock from Syros at the public offering price, less the underwriting disc... 
Printer Friendly Version
06/10/16Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidates at 21st Congress of the European Hematology Association
–SY-1425 Highlighted in Oral Presentation Showing Cancer Growth Inhibition and Prolonged Survival in Preclinical Model of Acute Myeloid Leukemia with a Novel Biomarker – – SY-1365 Induces Complete Tumor Regression and Extends Survival in Preclinical Models of Acute Leukemia –– Presentations Underscore Potential of Company’s Gene Control Platform to Identify and Drug Disease-Driving Targets –CAMBRIDGE, Mass., June 10, 2016 – Syros Pharmaceuticals today announced that SY-1425, its pote... 
Printer Friendly Version
06/01/16Syros Pharmaceuticals Appoints Industry Leader Sanj K. Patel to its Board of Directors
CAMBRIDGE, Mass., June 1, 2016 – Syros Pharmaceuticals today announced that Sanj K. Patel, Chief Executive Officer and Chairman of Kiniksa Pharmaceuticals, has been appointed to the Company's Board of Directors. Mr. Patel brings more than 25 years of biopharmaceutical industry experience, with a proven track record of developing and commercializing innovative therapies and building successful business enterprises. "With his extensive drug development, commercialization and leadership experience... 
Printer Friendly Version
05/31/16Syros Pharmaceuticals Announces FDA Acceptance of IND to Advance SY-1425 into Phase 2 Clinical Trial
Company On Track to Initiate Study in Mid-2016 in Genomically Defined Subsets of Patients with Acute Myeloid Leukemia and Myelodysplastic SyndromeCAMBRIDGE, Mass., May 31, 2016 – Syros Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) accepted the Company's Investigational New Drug (IND) application to advance its lead drug candidate, SY-1425, a potent and selective retinoic acid receptor alpha (RARα) agonist, into a Phase 2 clinical trial in genomically defined su... 
Printer Friendly Version
05/19/16Syros Pharmaceuticals to Present on its Two Lead Programs, SY-1425 and SY-1365, at 21st Congress of the European Hematology Association
SY-1425 for Genomically Defined Subsets of Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Selected for Oral Presentation CAMBRIDGE, Mass., May 19, 2016 – Syros Pharmaceuticals today announced that preclinical data on its lead program, SY-1425, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be highlighted in an oral presentation at the 21st Congress of the European Hematology Association (EHA) taking place J... 
Printer Friendly Version
04/20/16Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti-Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia
– Company on track to file IND in second half of 2016 and initiate Phase 1/2 clinical trial in acute leukemia in first half of 2017 –CAMBRIDGE, Mass., April 20, 2016 – Syros Pharmaceuticals today announced that SY-1365, a first-in-class potent and selective cyclin-dependent kinase 7 (CDK7) inhibitor, was observed to induce durable tumor regression and prolong survival in in vivo models of acute myeloid leukemia (AML). These data were presented at the American Association of Cancer Research (AACR... 
Printer Friendly Version
04/18/16Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Cancer Activity of SY-1425 in Preclinical Models of Acute Myeloid Leukemia
– Company on track to file IND and initiate Phase 2 study in mid-2016 in genomically defined subsets of AML and MDS patients identified by Syros' platform –CAMBRIDGE, Mass., April 18, 2016 – Syros Pharmaceuticals today announced that SY-1425, a potent and selective retinoic acid receptor alpha (RARα) agonist, was observed to inhibit the growth of cancer cells and prolong survival in in vivo models of acute myeloid leukemia (AML) with a novel RARA biomarker discovered by the Company. The biomarke... 
Printer Friendly Version
04/06/16Syros Pharmaceuticals to Present at 15th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., April 6, 2016 – Syros Pharmaceuticals announced today that Company executives will present a corporate overview at the 15th Annual Needham Healthcare Conference. The presentation will take place at 3 p.m. on April 12 at the Westin New York Grand Central Hotel in New York City.About Syros Pharmaceuticals Syros Pharmaceuticals is a biopharmaceutical company applying a pioneering approach to discover and develop medicines that control the expression of genes with the aim of treat... 
Printer Friendly Version
03/16/16Syros Pharmaceuticals to Present Preclinical Data on SY-1425 and CDK7 Inhibitor Program in Blood Cancers at Upcoming AACR Annual Meeting
Company's Lead Drug Candidates Demonstrate Therapeutic Potential in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Other Acute LeukemiasCAMBRIDGE, Mass., March 16, 2016 – Syros Pharmaceuticals today announced that it will present new preclinical data on its lead program SY-1425 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as on its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor program in acute leukemias. These data will be presented at... 
Printer Friendly Version
03/03/16Publication in Science Further Validates Importance of Gene Control Research in Yielding New Insights into Diagnosing and Treating Cancer
–New Class of Mutations in Non-Coding Regions of DNA Shown to Fuel Cancer Growth–CAMBRIDGE, Mass., March 3, 2016 – Syros Pharmaceuticals announced today that research from its scientific co-founder Richard Young, Ph.D., reveals a new mechanism by which genetic alterations in non-coding regions of the DNA fuel cancer growth, providing further validation for Syros' pioneering approach to discover and develop medicines that control the expression of genes with the aim of treating cancer and other s... 
Printer Friendly Version
03/03/16Syros Pharmaceuticals to Participate in Two Upcoming Conferences
CAMBRIDGE, Mass., March 3, 2016 – Syros Pharmaceuticals announced today that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at the upcoming BioCentury 23rd Annual Future Leaders in the Biotechnology Industry Conference. The Company's management team will also participate in next week's Cowen and Company 36th Annual Health Care Conference. Additional details are as follows: Cowen and Company 36th Annual Health Care Conference Date: Monday, March 7 to Wednesd... 
Printer Friendly Version
01/12/16Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing
– Company Advancing Pipeline of Clinical and Preclinical Product Candidates and Proprietary Gene Control Platform –CAMBRIDGE, Mass., January 12, 2016 – Syros Pharmaceuticals today announced the closing of a $40 million financing of preferred stock. New investor Deerfield Management Company led the financing, which also included participation from new investor Casdin Capital as well as existing investors Fidelity Management and Research Company, WuXi Healthcare Ventures, Polaris Partners, R... 
Printer Friendly Version